Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare Uroplasty to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.
Insider and Institutional Ownership
54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Uroplasty and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk and Volatility
Uroplasty has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s competitors have a beta of 0.47, meaning that their average stock price is 53% less volatile than the S&P 500.
This is a summary of recent ratings for Uroplasty and its competitors, as reported by MarketBeat.com.
||Strong Buy Ratings
As a group, “Medical Devices & Implants” companies have a potential upside of 36.60%. Given Uroplasty’s competitors higher possible upside, analysts plainly believe Uroplasty has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares Uroplasty and its competitors revenue, earnings per share and valuation.
Uroplasty’s competitors have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Uroplasty competitors beat Uroplasty on 6 of the 8 factors compared.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.